View Older Stories View More Recent Stories
-
Eli Lilly (LLY) PT Lowered to $875 at Guggenheim
-
Eli Lilly & Co. (LLY) CEO buys $1 million in stock
-
What to do with Novo Nordisk shares after recent volatility? Barclays explains
-
Eli Lilly & Co. (LLY) sued by Texas for allegedly bribing providers to prescribe company's medications
-
Buy this U.S. large-cap biopharma stock: JPMorgan
-
Bernstein Sees 'Clear Buying Opportunity' for Eli Lilly (LLY)
-
JPMorgan Reiterates Overweight Rating on Eli Lilly (LLY)
-
Eli Lilly (LLY) PT Lowered to $895 at UBS
-
Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY)
-
Novo shares rise for second day after Lilly obesity pills trails Wegovy in trial
-
Eli Lilly & Co. (LLY) options active on 358K contracts as share price pullback
-
Eli Lilly (LLY) PT Lowered to $905 at Jefferies
-
Leerink Partners Downgrades Eli Lilly (LLY) to Market Perform, 'we no longer expect upward pressure on long-term consensus expectations'
-
Eli Lilly shares slip 7% premarket as weight-loss pill study overshadows earnings
-
BofA Securities Reiterates Neutral Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Novo Nordisk shares jump as Eli Lilly obesity pill disappoints
-
Eli Lilly & Co. (LLY) Tops Q2 EPS by 72c; lifts guidance
-
Stocks expected to have increasing option volume: LLY BDX DDOG WBD QSR PODD RL ZBH H CELH ELAN CROX YETI WRBY PTON
-
Eli Lilly Q2 earnings preview: analysts eye obesity drug sales momentum
-
Eli Lilly & Co. (LLY) call put ratio 1 call to 1 put into quarter results
-
Eli Lilly & Co. (LLY) call put ratio 2.2 calls to 1 put into quarter results
-
Bernstein on Eli Lilly (LLY): 'We've Been Waiting for This'
-
Novo Nordisk (NVO) stock: Where next after profit warning?
-
Trump admin to pilot coverage of weight‑loss drugs under Medicare and Medicaid - WaPo
-
White House: Trump took action on pharma Thursday, sent letters to CEOs
-
White House: calls on Eli Lilly to take actions within 60 days
-
Lilly stock falls as Mounjaro fails to show superiority over Trulicity
-
Lilly's Mounjaro shows cardiovascular protection in head-to-head trial
-
Deutsche Bank defends Eli Lilly (LLY) on Novo-related sell-off
-
Eli Lilly (LLY) PT Raised to $920 at BMO Capital
-
Hims & Hers (HIMS) reportedly makes statement on congressional letter to FDA
-
Hims & Hers Health, Inc. (NYSE: HIMS) Falls, Group Of 81 Bipartisan Lawmakers Sign Letter On Glp-1 Action
-
Lilly completes Verve Therapeutics acquisition for cardiovascular treatments
-
Eli Lilly receives positive opinion for donanemab in Europe
-
Lilly tender offer for Verve expires with 55.7% of shares tendered
-
BMO Capital on Eli Lilly (LLY): 'ALZ 3 Interim Could Read Positively in Near Future'
-
15 names that Morgan Stanley’s analysts expect to move meaningfully on earnings
-
Eli Lilly (LLY) PT Raised to $942 at Guggenheim
-
FDA approves updated dosing for Lilly's Kisunla Alzheimer's treatment
-
Eli Lilly & Co. (LLY) call put ratio 9.5 calls to 1 put with a focus on a spreader of July 850, and 960 calls
-
JPMorgan Reiterates Overweight Rating on Eli Lilly (LLY)
-
Morgan Stanley on Compounder Lawsuits: 'experts think the courts would likely refuse to dismiss the case and that it could take 2-3 years to resolve'
-
RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimer’s market
-
UBS Reiterates Buy Rating on Eli Lilly (LLY)
-
BMO Capital Downgrades Verve Therapeutics (VERV) to Market Perform
-
Eli Lilly & Co. (LLY) announced FDA approval of updated label for Lilly’s Amyvid (florbetapir F 18 injection) to support diagnosis of Alzheimer’s disease in patients
-
Chardan Comments on iBio, Inc. (IBIO)
-
Citi bullish on Lilly as Orforglipron unlocks $40B+ obesity market
-
Citi Reiterates Buy Rating on Eli Lilly (LLY)
-
BMO Capital on Eli Lilly (LLY): 'Is It Time to BELIEVE?'
